Meta-Analysis Confirms Trastuzumab Deruxtecan Efficacy in HER2-Positive Gastrointestinal Cancers
Key Insights
A comprehensive meta-analysis of 653 patients across 10 studies demonstrates that trastuzumab deruxtecan achieves a pooled objective response rate of 36.9% in HER2 (search)-positive gastrointestinal malignancies.
The antibody-drug conjugate shows median overall survival of 11.15 months and progression-free survival of 5.6 months, even in heavily pretreated patients who received at least two prior therapies.
Safety analysis reveals manageable adverse events with nausea being most common (47.9%), while serious interstitial lung disease occurs in only 1.6% of patients at grade 3/4 severity.
A systematic review and meta-analysis of 653 patients across 10 clinical studies has provided comprehensive evidence supporting the efficacy and safety of trastuzumab deruxtecan (T-DXd) in treating HER2 (search)-positive gastrointestinal malignancies. The analysis, conducted following PRISMA guidelines, represents the largest pooled dataset evaluating this antibody-drug conjugate in GI cancers.
Robust Clinical Activity Demonstrated
The meta-analysis revealed a pooled objective response rate (ORR) of 36.9% (95% CI: 31.5%-42.5%) among patients with HER2 (search)-positive GI malignancies. The median overall survival reached 11.15 months (range: 1.4-20.8), while progression-free survival was 5.6 months (2.6-8.7). The median duration of response was 7 months (0.7-22.3), indicating durable clinical benefit.
Partial response rates accounted for 35.2% of patients (95% CI: 31.1%-39.5%), while complete responses were achieved in 1.3% (95% CI: 0.0%-4.7%). The disease control rate, including stable disease, reached 34.4% (95% CI: 27.6%-41.5%), demonstrating T-DXd's ability to halt disease progression even when complete or partial responses are not achieved.
HER2 Expression Levels Impact Outcomes
The analysis revealed significant differences in treatment response based on HER2 (search) expression levels. Patients with HER2 IHC 3+ tumors demonstrated superior outcomes compared to those with HER2 2+/ISH-positive disease. In one study, HER2 IHC 3+ patients achieved a 58% response rate versus 29% in the HER2 2+/ISH-positive group.
For colorectal cancer specifically, patients with HER2 (search) IHC 3+ or HER2 2+/ISH-positive status exhibited a 45% partial response rate, while no partial responses were observed in patients with HER2 2+/ISH-negative status. The duration of response was also significantly longer in the higher HER2 expression group, averaging 7 months compared to no response in the HER2 2+/ISH-negative cohort.
Dosing Considerations and Safety Profile
The majority of patients (84%) received the 6.4 mg/kg dose, while 59.5% of a subset received the 5.4 mg/kg dose. Dose-related efficacy differences were observed, with some studies reporting better outcomes at specific dosing levels, though results varied across trials.
Safety analysis demonstrated that T-DXd is generally well-tolerated. The most common adverse event was nausea, affecting 47.9% of patients (95% CI: 29.4%-66.7%), though grade 3/4 nausea occurred in only 3.7% of cases. Hematologic toxicities included anemia in 36.6% of patients (grade 3/4: 17.4%) and neutropenia in 32.5% (grade 3/4: 18.1%).
Interstitial lung disease (ILD) or pneumonitis, a serious but rare adverse event, occurred in 8.8% of patients overall, with grade 3/4 severity in 1.6% of cases. Treatment discontinuation due to toxicities occurred in 15% of patients, while treatment-related mortality was 2.9%.
Patient Population and Treatment History
The study population had a median age of 64.5 years (range: 27-85), with 53% being male. Importantly, 70% of patients had HER2 (search) IHC 3+ tumors, while 26% had HER2 2+/FISH-positive disease. All patients were heavily pretreated, having received at least two prior therapies (range: 1-11), and 65% had previously received HER2-targeted treatment.
Performance status appeared to influence outcomes, with patients having an ECOG score of 0 achieving a 54% response rate compared to 25% for those with an ECOG score of 1. This suggests that earlier intervention with T-DXd may yield better results.
Implications for Clinical Practice
The meta-analysis validates T-DXd as an effective treatment option for HER2 (search)-positive GI malignancies, even in heavily pretreated patients. The moderate but clinically meaningful response rate, combined with manageable toxicity, supports its use in this challenging patient population.
The data particularly highlight the importance of accurate HER2 (search) testing, as higher expression levels correlate with better outcomes. The findings also suggest potential benefits of earlier treatment intervention, given the performance status-related differences in response rates.
While the response rates in GI malignancies (36.9%) are lower than those reported in HER2 (search)-positive breast cancer (66.9%) and lung cancer (55.6%), the clinical benefit remains substantial for a patient population with limited treatment options. The analysis supports continued investigation of T-DXd in earlier treatment lines and potential combination strategies for GI malignancies.